Business Description
Great Novel Therapeutics Biotech & Medicals
ISIN : TW0007427007
Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.15 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 48.43 | |||||
| Beneish M-Score | 4.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 3.5 | |||||
| 3-Year EPS without NRI Growth Rate | 0.7 | |||||
| 3-Year FCF Growth Rate | 12.6 | |||||
| 3-Year Book Growth Rate | 33.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.14 | |||||
| 9-Day RSI | 45.73 | |||||
| 14-Day RSI | 48.8 | |||||
| 6-1 Month Momentum % | -14.51 | |||||
| 12-1 Month Momentum % | -30.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 30.47 | |||||
| Quick Ratio | 30.08 | |||||
| Cash Ratio | 29.91 | |||||
| Days Inventory | 1006.16 | |||||
| Days Sales Outstanding | 191.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.8 | |||||
| Shareholder Yield % | -14.81 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.92 | |||||
| Operating Margin % | -1368.31 | |||||
| Net Margin % | -1268.87 | |||||
| FCF Margin % | -1530.06 | |||||
| ROE % | -11.4 | |||||
| ROA % | -10.84 | |||||
| ROIC % | -44.83 | |||||
| ROC (Joel Greenblatt) % | -597.5 | |||||
| ROCE % | -11.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 397.07 | |||||
| PB Ratio | 3.49 | |||||
| Price-to-Tangible-Book | 4.26 | |||||
| EV-to-EBIT | -27.52 | |||||
| EV-to-EBITDA | -30.8 | |||||
| EV-to-Revenue | 348.71 | |||||
| EV-to-FCF | -23.06 | |||||
| Price-to-Net-Current-Asset-Value | 4.7 | |||||
| Price-to-Net-Cash | 4.79 | |||||
| Earnings Yield (Greenblatt) % | -3.63 | |||||
| FCF Yield % | -3.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Great Novel Therapeutics Biotech & Medicals Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 4.85 | ||
| EPS (TTM) (NT$) | -1.635 | ||
| Beta | 0 | ||
| Volatility % | 34.24 | ||
| 14-Day RSI | 48.8 | ||
| 14-Day ATR (NT$) | 2.660614 | ||
| 20-Day SMA (NT$) | 54.866439 | ||
| 12-1 Month Momentum % | -30.76 | ||
| 52-Week Range (NT$) | 42.851719 - 106.287655 | ||
| Shares Outstanding (Mil) | 39.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Great Novel Therapeutics Biotech & Medicals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Great Novel Therapeutics Biotech & Medicals Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Great Novel Therapeutics Biotech & Medicals Frequently Asked Questions
What is Great Novel Therapeutics Biotech & Medicals(ROCO:7427)'s stock price today?
The current price of ROCO:7427 is NT$54.00. The 52 week high of ROCO:7427 is NT$106.29 and 52 week low is NT$42.85.
When is next earnings date of Great Novel Therapeutics Biotech & Medicals(ROCO:7427)?
The next earnings date of Great Novel Therapeutics Biotech & Medicals(ROCO:7427) is .
Does Great Novel Therapeutics Biotech & Medicals(ROCO:7427) pay dividends? If so, how much?
Great Novel Therapeutics Biotech & Medicals(ROCO:7427) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers